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HBV has two enhancer (En) regions each of which promotes its own transcription. En II regulates
production of pregenomic RNA, a key product of HBV replication, more strongly than En I. Although
IFN-a has been found to suppress En I activity, its effect on En II activity has not been examined. Here
we used luciferase assay to demonstrate that IFN-a suppresses En II activity. Analysis with several
deletion/mutation constructs identiﬁed two major segments, nt 1703–1727 and nt 1746–1770, within
the En II sequence as being responsible for the suppressive effects of IFN-a. Pre-treatment with protein
kinase C (PKC) inhibitors blocked this effect regardless of the expression levels of phospho-STAT1 and
Mx upon IFN-a stimulation. These results indicate that IFN-a suppresses En II activity via the PKC
pathway, which may be an alternative suppressive pathway for HBV replication. (136 words).
& 2012 Elsevier Inc. All rights reserved.Introduction
Hepatitis B virus (HBV) causes acute and chronic hepatitis in
humans, and chronic infection is closely associated with the devel-
opment of liver cirrhosis and hepatocellular carcinoma (Lok and
McMahon, 2009). HBV has a partially double-stranded 3.2-kb DNA
genome (relaxed circular (RC) DNA) in its nucleocapsid. When HBV
invades host cells, RC-DNA is converted into a plasmid-like covalently
closed circular DNA (cccDNA) inside the nucleus. From the cccDNA,
the 3.5-, 2.4-, 2.1-, and 0.8-kb mRNAs are transcribed by cellular RNA
polymerase II (Beck and Nassal, 2007). Among these RNAs, 3.5-kb
pregenomic RNA (pgRNA) serves as the template of reverse transcrip-
tion for synthesis of negative-strand DNA. Thus, transcription of
pgRNA from cccDNA is one of the key steps in HBV replication.
In the HBV genome, there are four promoters (CP, SPI, SPII, and
XP) and two transcriptional enhancer regions. Both enhancers
stimulate transcription from the promoters (Antonucci and Rutter,
1989; Moolla et al., 2002; Su and Yee, 1992; Vannice and Levinson,
1988; Yee, 1989). Enhancer I (En I), which is located upstream of the
X gene, activates transcription in a relatively cell-independent
manner (Vannice and Levinson, 1988). In contrast, enhancer II (En
II) (Fig. 1), located just upstream of CP, speciﬁcally activatesll rights reserved.
. Takehara).
nd share ﬁrst authorship.transcription in hepatocytes (Wang et al., 1990; Yee, 1989; Yuh
and Ting, 1990). Hepatocytes selectively express transcription fac-
tors which activate En II activity, such as HNF1 (Wang et al., 1998),
HNF3 (Johnson et al., 1995; Li et al., 1995), HNF4 (Guo et al., 1993;
Raney et al., 1997), CCAAT/enhancer binding protein (C/EBP) (Lo´pez-
Cabrera et al., 1990, 1991; Yuh and Ting, 1991) and FTF (Ishida et al.,
2000; Li et al., 1998). This characterizes En II as a hepatocyte-speciﬁc
cis-acting element. A previous report showed that, upon transfection
with HBV genome, human hepatic cells, but not non-hepatic cells,
were able to express pgRNA (Sureau et al., 1986). For this reason, En
II is considered to regulate the production of pgRNA more strongly
than En I (Yee, 1989).
Interferon-a (IFN-a) has been used as an anti-viral agent against
HBV. It suppresses HBV viral load and ameliorates hepatic inﬂam-
mation (Jonas et al., 2010; Liaw, 2009). Type I IFN activates the Janus
kinase (JAK) bound to the cytoplasmic domain of its receptor. JAK
phosphorylates transcription factors such as signal transducers and
activators of transcription (STAT) 1 and STAT2. Phosphorylated
STAT1 and STAT2 bind to IFN regulatory factor 9 (IRF9). These
transcription factors form a complex, IFN-stimulated gene factor 3
(ISGF3). This complex binds to IFN stimulation response element
(ISRE) in the promoter region of various genes, and activates
interferon-stimulated genes (ISGs) (Der et al., 1998). Some of the
ISGs including RNA-activated protein kinase (PKR), 20,50-oligoade-
nylate synthetases (OAS), and Mx have been shown to possess
antiviral activity. ISG induction by type I IFN is considered to be the
main pathway to suppressing viral replication.
Fig. 1. Nucleotide sequences of the HBV En II region. The HBV sequence used in this study was of the adw2 subtype (GenBank accession no. X02763). Numbering of the
HBV sequence started at the unique EcoRI site. The underlined sequences represent the transcription factor binding sites mentioned in previous reports.
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promoter activities (Nakao et al., 1999; Romero and Lavine, 1996;
Schulte-Frohlinde et al., 2002; Tur-Kaspa et al., 1990). Nakao et al.
demonstrated that IFN-a suppressed En I transcriptional activity
by the binding of ISGF3 to the ISRE-like sequence in En I region
(Nakao et al., 1999). However, there has been no study on the
effect of IFN-a on HBV En II activity. In this study, we demon-
strated that IFN-a suppressed En II activity via activation of PKC.
Notably, STAT1 activation and ISG induction may be dispensable
for IFN-a-mediated suppression of En II activity. This might shed
light on understanding the inhibition of HBV replication by IFN-a.Results
En II activity is down-regulated by IFN-a
We constructed a luciferase gene expression vector by inserting
the En II sequence (nt 1640 to 1771) into pGL4LUC (pGL4LUC-En II).
Huh-7 cells were transfected with pGL4LUC or pGL4LUC-En II,
treated with or without IFN-a, and luciferase activities were
evaluated. Insertion of En II increased the luciferase activity (about
228-fold) (Fig. 2A). IFN-a down-regulated the luciferase activity of
pGL4LUC-En II, but did not affect that of pGL4LUC (Fig. 2B). This
result suggested that IFN-a inhibited the activity of En II, and we
examined the time course of IFN-a-induced suppression of En II
activity. The suppressive effect of IFN-a on En II activity appeared at
3 h after administration of IFN-a, peaked at 6–12 h, and was
gradually attenuated (Fig. 2C). Next, dose-response analysis showed
that the En II activity was down-regulated by IFN-a in a dose-
dependent manner, with the maximal suppressive effect at 300–
1000 IU/m (Fig. 2D). We also examined the IFN-a-mediated sup-
pression of En II activity in other hepatoma cell lines, PLC/PRF/5 and
Hep3B. IFN-a signiﬁcantly suppressed En II activities in both these
cell lines (Fig. 2E). We next assessed whether or not IFN-a regulated
HBV transcription in the HBV genome transfected cells by RT-PCR.
HBV-RNA levels were signiﬁcantly reduced by IFN-a (Fig. 2F). These
results indicate that IFN-a suppresses HBV En II activity as well as
its expression at a transcriptional level.
Both nt 1703–1727 and nt 1746–1770 within the En II region are
required for suppression of En II activity by IFN-a
To determine the region responsible for the inhibitory effect of
IFN-a on En II activity, we divided the En II sequence into six
segments (Fig. 3A), and constructed plasmids containing En IIsequences with deletion of each segment (pGL4LUC-En II-D16).
Huh-7 cells were transfected with these deleted constructs,
treated with IFN-a, and then assayed for luciferase activity. None
of the deletions could restore the suppressive activity by IFN-a
(Fig. 3B), suggesting that there are several responsible regions for
the IFN-a-induced suppression of En II activity. Next, we con-
structed plasmids containing four iterations of each segment
within the En II sequence in tandem (pGL4LUC-En II-T16) to
examine the contribution of individual short fragments. IFN-a
signiﬁcantly suppressed the activities of pGL4LUC-En II-T2, T3, T4,
T5 and -T6 in luciferase assay. Among them, the activities of
pGL4LUC-En II-T4 and -T6 showed the largest suppression by IFN-
a (Fig. 3C). On the basis of this result, we constructed a luciferase
reporter vector with deletions of both segment 4 (nt 1703–1727)
and segment 6 (nt 1746–1770) (pGL4LUC-En II-D4þ6). The
activity of this dual-deleted construct did not show a signiﬁcant
change due to IFN-a (Fig. 3D). These results suggest that both nt
1703–1727 and nt 1746–1770 within the En II region are required
for the suppression of En II activity by IFN-a.
IFN-a-mediated suppression of En II activity is dependent on JAK
activation
IFN-induced signal transduction occurs through the sequential
activation of JAKs and STATs (Darnell et al., 1994). We examined
the role of JAK in the inhibition of En II activity. JAK inhibitor
alone did not affect En II activity. But the pre-treatment of the
cells with JAK inhibitor completely blocked the suppressive effect
of IFN-a on En II activity (Fig. 4A). The effect of JAK inhibitor was
conﬁrmed by the reducion of Mx induction in Western blot
analysis (Fig. 4B). This result demonstrates that JAK activation is
necessary for the IFN-a-induced suppression of En II activity.
The PKC pathway is involved in IFN-a-mediated suppression of En II
activity
Previous reports demonstrated that type I IFN activated
various kinases such as MAPK family members (MEK/ERK and
p38 MAPK) (David et al., 1995; Goh et al., 1999), PI3K/Akt (Uddin
et al., 1995), JNK (Caraglia et al., 1999) and protein kinase C (PKC)
(Uddin et al., 2002). Here we examined the involvement of
alternative pathways by pre-treatment with inhibitors for various
kinases, including MEK, p38 MAPK, PI3K/Akt, JNK and PKC. The
name of each inhibitors and its target kinase is commented in
Table 1. As shown in Fig. 5A, only staurosporine, a PKC inhibitor,
blocked the inhibitory effect of IFN-a, and other inhibitors did
Fig. 2. Suppression of HBV En II transcriptional activity and reduction of HBV-RNA by IFN-a. A, B. Huh-7 cells were transfected with pGL4LUC or pGL4LUC-En II or
incubated with or without IFN-a (100 IU/ml). After 24 h, the activity of ﬁreﬂy luciferase was evaluated. C. Huh-7 cells were transfected with pGL4LUC-En II, and incubated
with IFN-a (100 IU/ml). Luciferase activities were evaluated at the indicated times. D. Huh-7 cells were transfected with various concentrations (0–1000 IU/ml) of IFN-a for
12 h and luciferase activities were evaluated. E. PLC/PRF/5 cells (left panel) and Hep3B (right panel) cells were transfected with pGL4LUC-En II, and incubated with or
without IFN-a (300 IU/ml). Luciferase activities were evaluated. F. Huh-7 cells were transfected with pHBV1.5, and treated with IFN-a at various concentrations
(0–1000 IU/ml). At 72 h after IFN-a treatment, cells were harvested, and the abundances of HBV-RNA were evaluated by quantitative RT-PCR. The HBV-RNA level of the
IFN-a treated cells was normalized with that of non-treated cells. npo0.05. ‘‘/control’’ on the vertical axis means the ratio of luciferase activity of IFN-a treated cells
normalized with that of non-treated cells.
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trum activity (Marte et al., 1994), we also examined other
inhibitors speciﬁc for PKC isoforms. Previous reports demon-
strated that IFN-a activated PKC-a/b and PKC-d (Pfeffer et al.,
1990; Uddin et al., 2002). Indeed, activation of PKC-a/b and PKC-d
by IFN-a was conﬁrmed by immunoblot analysis (Fig. 5B). Thus,
we examined the PKC inhibitors rottlerin and Go¨6976
(Gschwendt et al., 1994; Martiny-Baron et al., 1993). All PKC
inhibitors blocked the suppression of En II activity by IFN-a
(Fig. 5C). These results suggest that several isoforms of PKC are
involved in the IFN-a-mediated suppression of En II activity. We
also examined STAT1 activation and ISGs induction by IFN-a in
cells pre-treated with these PKC inhibitors using immunoblot
analysis (Fig. 5D). Expression levels of phospho-STAT1 and Mx
differed among these PKC inhibitors. Staurosporine and Go¨6976
slightly diminished the activation of STAT1, but rottlerin did not.
This result suggests that PKC isoforms might not strongly regulateactivation of STAT1. Rottlerin, a speciﬁc inhibitor for PKC-d,
inhibited the induction of Mx, which agreed with previous
ﬁndings (Kaur et al., 2005). Staurosporine and Go¨6976 did not
suppress Mx expression. Taken together, all these PKC inhibitors
blocked the suppression of En II activity by IFN-a regardless of the
expression levels of phospho-STAT1 and Mx. These results sug-
gest that STAT1 activation and ISG induction may be dispensable
for the IFN-a-mediated suppression of En II activity. Next, we
examined the effect of phorbol 12-myristate 13-acetate (PMA), a
PKC activator (Castagna et al., 1982; Griner and Kazanietz, 2007).
PMA suppressed En II activity (Fig. 5E), and PMA stimulation did
not result in STAT1 phosphorylation and Mx induction (Fig. 5F),
suggesting that suppression of En II by PMA is independent of
STAT1 activation and ISG induction. On the basis of these ﬁndings,
we conclude that IFN-a suppresses En II activity via the PKC
pathway, which may not involve STAT1 activation and ISG
induction.
Fig. 3. Deletion/mutational analysis to identify the responsive sequence for the suppressive effect of IFN-a on En II. A. Scheme of pGL4LUC-En II and six segments deﬁned
within the En II sequence. The En II sequence was integrated just upstream of the minimal promoter of pGL4LUC. B. Huh-7 cells were transfected with the reporter vectors
with deletion of each segment (pGL4LUC-En II-D16), incubated with 300 IU/ml IFN-a for 12 h, and luciferase activities were evaluated. C. Plasmids containing four
iterations of each segment within En II sequence in tandem (pGL4LUC-En II-T16) were generated and luciferase activities were evaluated similarly. D. Plasmid with
deletion of both nt 1703–1727 and nt 1746–1770 (pGL4LUC-En II-D4þ6) was constructed and luciferase activities were evaluated similarly. npo 0.05. ‘‘/control’’ on the
vertical axis means the ratio of luciferase activity of IFN-a treated cells normalized with that of non-treated cells.
Fig. 4. Involvement of JAK activation in the IFN-a-induced suppression of En II
activity. A. Huh-7 cells were transfected with pGL4LUC-En II and treated with JAK
inhibitor (1 mM) for 1 h. The cells were then incubated with IFN-a(150 IU/ml) for
12 h, followed by luciferase assay. B. Huh-7 cells were pre-treated with JAK
inhibitor for 1 h, and then incubated with IFN-a(150 IU/ml) for 12 h, followed by
immunoblot analyses to detect Mx protein. npo0.05. ‘‘/control’’ on the vertical
axis means the ratio of luciferase activity of IFN-a treated cells normalized by that
of non-treated cells.
Table 1
A comment of the inhibitors and its target kinase.
PD98059 MEK inhibitor
SB203580 P38MAPK inhibitor
LY294002 PI3K inhibitor
Akt-1-1/2 Akt inhibitor
SP600125 JNK inhibitor
Staurosporine PKC inhibitor with broad spectrum
Rottlerin Inhibitor speciﬁc for PKC-d
Go¨6976 Inhibitor speciﬁc for Ca2þ-dependent PKC isoforms
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induced suppression of En II activity
We anticipated that IFN-a suppressed En II activity by functional
down-regulation of some transcription factor(s) phosphorylated in a
PKC-dependent manner. Among transcription factors which bind
the En II region, previous reports showed that Speciﬁcity Protein 1
(Sp1) (Mahoney et al., 1992; Pal et al., 1998; Rafty and Khachigian,2001), Retinoid X Receptor a (RXRA) (Delmotte et al., 1999) and
C/EBP (Mahoney et al., 1992) were inactivated by PKC. Thus, we
examined the En II response to IFN-a after knockdown of these
transcription factors. C/EBP, RXR and Sp1 expression was efﬁciently
reduced by siRNA (Fig. 6A). We observed no signiﬁcant change in
the suppression of En II activity compared with control siRNA
(Fig. 6B). This result suggests that several transcription factors
(including unknown proteins) might be involved in the IFN-a-
mediated suppression of En II activity.Discussion
In the present study, we demonstrated that IFN-a suppressed
HBV En II activity. The inhibition by IFN-a of En II activity could
be blocked by pre-treatment with PKC inhibitors, and this
Fig. 5. PKC-dependent suppression of En II activity by IFN-a. A and C. Huh-7 cells were transfected with pGL4LUC-En II, treated separately with each kinase inhibitor for
1 h. The cells were then treated with IFN-a(1000 IU/ml) for 12 h, and luciferase activities were evaluated. B. Huh-7 cells were treated with IFN-a(1000 IU/m) for 12 h.
Immunoblot analyses were performed to detect phosphorylated PKC-a/b and phosphorylated PKC-d. Quantitative analysis of the expression level of phopho- PKC-a/b and
-d was performed by using ImageJ. Each level was normalized with that of IFN-a-non-treated cells. D. Huh-7 cells were harvested at 30 min to detect phosphorylated
STAT1 and at 12 h to detect the expression of Mx after administration of IFN-a (1000 IU/m), and immunoblot analyses were performed. Quantitative analysis of the
expression level of phopho-STAT1 was performed by using ImageJ. Each level was normalized with that of IFN-a-non-treated cells. E. Huh-7 cells were transfected with
pGL4LUC-En II, treated with PMA (100 nM) for 12 h, and luciferase activities were evaluated. F. Huh-7 cells were treated with PMA (100 nM) or IFN-a(1000 IU/m). The cells
were harvested at 30 min to detect phosphorylated STAT1 and at 12 h to detect the expression of Mx, and immunoblot analyses were performed. npo0.05. ‘‘/control’’ on
the vertical axis means the ratio of luciferase activity of IFN-a/ PMA treated cells normalized with that of non-treated cells.
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tion. The latter, ISG induction via the JAK-STAT pathway, has been
considered to be the main mechanism suppressing viral replica-
tion. Our ﬁndings suggest a pathway for IFN-a repression of HBV
transcription other than ISG induction.
PKCs are involved in a wide variety of cell functions and signal
transduction pathways regulating cell migration and polarity,
proliferation, differentiation and cell death (Nishizuka, 1988). In
the PKC family, there are at least ten isoforms which can be
divided into three sub-groups based on their structural charac-
teristics and cofactor requirements. These include the classical
PKC (cPKC: a, bI, bII, and g), the novel PKC (nPKC: d, e, Z and y),
and the atypical PKC (aPKC: z and i/l) (Azzi et al., 1992;Breitkreutz et al., 2007; Kikkawa et al., 1989). IFN-a can activate
multiple PKC isoforms: not only PKC-d, but also PKC-a/b (Pfeffer
et al., 1990), PKC-e (Pfeffer et al., 1991), and PKC-y (Srivastava
et al., 2004). Despite the variety of PKC isoforms, most phosphor-
ylate similar sequences (Breitkreutz et al., 2007). Both the
PKC-a/b inhibitor (Go¨6976) and PKC-d inhibitor (rottlerin)
blocked the inhibitory effect of IFN-a on En II activity. Thus, it
was speculated that each PKC isoform might be similarly involved
in suppressing of En II activity.
Other studies have examined the role of the PKC pathway in
HBV replication. Kang et al. (2008) reported that PKC-mediated
phosphorylation increased capsid assembly and stability (von
Hahn et al., 2011), and von Hahn et al. (2011) reported that the
Fig. 6. IFN-a-mediated suppression on En II activity with knockdown of C/EBP,
RXR and Sp1. A. Huh-7 cells were transfected with 10 nM siRNA (negative control
or speciﬁc for C/EBP, RXR and Sp1). Immunoblot analyses for expressions of C/EBP,
RXR, Sp1 and b-actin were performed at 48 h post siRNA transfection. B. Huh-7
cells were transfected with 10 nM siRNA (negative control or speciﬁc for C/EBP,
RXR and Sp1). On the next day, si-RNA treated cells were transfected again with
pGL4LUC-En II. On the following day, these transfected cells were incubated with
IFN-a(1000 IU/ml) for 12 h, and luciferase activities were evaluated. ‘‘/control’’ on
the vertical axis means the ratio of luciferase activity of IFN-a treated cells
normalized with that of non-treated cells.
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the role of PKC in the HBV life cycle is still controversial, our ﬁndings
suggest that PKC isoforms activated by IFN-a play inhibitory roles in
HBV transcription by down-regulation of En II activity. As von Hahn
et al. reported, sotrastaurin alone did not affect HBV replication. But,
based on our present data about another pan-PKC inhibitor, staur-
osporine, we speculate that sotrastaurin may also block the inhibi-
tory effect of IFN-a on En II activity.
We showed that knockdown of a single transcription factor did
not inﬂuence the IFN-a-mediated suppression of En II activity,
suggesting that several transcription factors might be involved in
this suppression. We also showed that both segment 4 (nt 1703–
1727) and segment 6 (nt 1746–1770) within the En II region are
required for the IFN-a-induced suppression of En II activity.
Although these two regions seem to be more important than
the others, all the deleted version of reporter constructs showed
almost completely similar suppression activities (Fig. 3B). We
speculate that there may be some transcription factors which
affect both the segment 4 and 6. Even if one of these regions is
deleted, some factors may affect the other region, and result in
the suppression of En II activity. Further study will be needed to
clarify the mechanism.
Indeed, there are no identiﬁed transcription factors which
could bind both segment 4 and 6. Only two transcription factors
(HNF1 and 3) were reported to bind segment 4 (Johnson et al.,
1995; Wang et al., 1998), and there have been no reports
indicating that IFN-a or PKC inactivates HNF1 or 3. We also
examined the expression levels of HNF1 and 3 of the IFN-a
treated and the non-treated cells by RT-PCR. There was no
signiﬁcant difference in the expression of these transcription
factors between the IFN-a treated and the non-treated cells
(Nawa et al., unpublished data). Thus, we speculate that HNF1
or 3 might not be involved in the IFN-a mediated suppression of
En II activity. There may be unknown transcription factors in the
PKC pathway.Previous reports showed that IFN-a suppressed En I activity
(Nakao et al., 1999; Tur-Kaspa et al., 1990). Nakao et al. (1999)
indicated that this occurred due to the binding of ISGF3 to an
ISRE-like motif within the En I region. However, Rang et al. (2001)
demonstrated that IFN-a reduced HBV-RNA levels derived from
both HBV genome wild type and mutated ISRE-like motifs. This
result contradicted the Nakao’s result that the activity of the En I
mutated ISRE-like motif was not suppressed by IFN-a. Schulte-
Frohlinde et al. (2002) reported that IFN-a suppressed HBV core
promoter regulated transcriptional activity, even when the ISRE-
like motif of En I was deleted. The results of Rang et al. and
Schulte-Frohlinde et al. suggest that IFN-a might suppress the
activity of regions other than En I. In the present study, we
demonstrated that IFN-a suppressed En II activity via the PKC
pathway. En II might be one of the candidate regions down-
regulated by IFN-a within the HBV genome.
Since En II activates viral transcription only in hepatocytes, it
is responsible for the hepatocyte-speciﬁc gene expression of HBV.
There had been no study on the effect of IFN-a on En II activity.
Our study clariﬁed that the PKC pathway is involved in the IFN-a-
mediated suppression of En II activity, but may not involve ISG
induction. Our result should aid in establishing better treatment
with IFN-a against HBV infection. As we could not determine the
molecule which inhibits En II activity by IFN-a, further study is
needed to clarify this molecule and to control hepatitis B by IFN-a
treatment.Materials and methods
Plasmids
The HBV sequence used in this study was of the adw2 subtype
(GenBank accession no. X02763). Numbering of the HBV sequence
started at the unique EcoRI site. The En II region in this study was
deﬁned as nt 1640–1771 of HBV sequence (Fig. 1) (Ishida et al.,
2000). To construct pGL4LUC-En II, a plasmid containing the HBV
En II region, the DNA fragment was ampliﬁed with PCR and
inserted between Hind III and Nhe I site of pGL4 Luciferase
Reporter Vector (pGL4LUC) (Promega, Madison, WI). The PCR
primers were as follows: 50-CCAAGCTTCTGCCCAAGGTC-30 and
50-CCCGCTAGCAAAGACCTTTAACCTAATCTCCTCC-30. The constructs
of the En II sequence with various deletions were generated by
modifying pGL4LUC-En II using the QuikChange Site-Directed Muta-
genesis Kit (Stratagene, La Jolla, CA). The constructs containing four
tandem repeats of short fragment in En II sequence were generated
by inserting duplexes of synthesized oligonucleotides into the multi-
cloning site of pGL4LUC. All of the En II sequences were inserted in
the antisense orientation to evaluate their enhancer activity.
Plasmid pHBV1.5 containing a 1.5-fold-overlength genome of
HBV-DNA (GenBank accession no. AF305422) has been described
previously (Bruss and Ganem, 1991).Cell lines and reagents
The human hepatocellular carcinoma cell lines Huh-7, PLC/PRF/5,
and Hep3B were cultured in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) supplemented with 10% heat-inactivated fetal bovine
serum (Sigma-Aldrich, St. Louis, MO) in a humidiﬁed incubator at
5% CO2 and 37 1C. Human natural IFN-a was kindly provided by
Hayashibara Biochemical Laboratories, Inc. (Okayama, Japan).
The inhibitors/activators and the ﬁnal concentrations used
were: JAK inhibitor I (1 mM), PD98059 (10 mM), SB203580
(10 mM), LY294002 (10 mM), Akt-I-1/2 (5 mM), staurosporine (10
or 20 nM), rottlerin (5 mM), Go¨6976 (1 mM), SP600125 (10 mM)
T. Nawa et al. / Virology 432 (2012) 452–459458(Calbiochem, San Diego, CA), phorbol 12-myristate 13-acetate
(PMA) (100 nM) (Sigma-Aldrich, St. Louis, MO).
Plasmid transfection and luciferase assay
Huh-7 cells were co-transfected with the ﬁreﬂy luciferase
plasmid and pGL4-RL-tk, an expression vector of renilla luciferase,
which was used as an internal control, using FuGENE HD reagent
(Roche Applied Science, Indianapolis, IN) according to the man-
ufacturer’s protocol. Activities of ﬁreﬂy luciferase and renilla
luciferase were measured using the Dual-Glo Luciferase Assay
System (Promega, Madison, WI), and then relative luciferase
activity was calculated by normalizing ﬁreﬂy luciferase activity
to renilla luciferase activity.
RNA extraction
Total RNA was isolated from cells using ISOGEN (Nippon Gene,
Tokyo, Japan) according to the manufacturer’s protocol. The
isolated RNA was treated with DNase I (Promega, Madison, WI)
to avoid contamination with transfected plasmid, and then
puriﬁed with a mixture of phenol, chloroform, and isoamylalcohol
(pH 7.9), followed by ethanol precipitation.
Western blot analysis
Cultured cells were lysed with a lysis buffer (1% NP-40, 0.5%
sodium deoxycholate, 0.1% SDS, and protein inhibitor cocktail
(Nacalai Tesque), in PBS, pH 7.4). Equal amounts of protein were
electrophoretically separated by polyacrylamide gel and transferred
onto PVDF membrane. For immunodetection, the following
antibodies were used: anti-STAT1 antibody, anti-phospho-STAT1
antibody, anti-phospho-PKC-a/b II (Thr 638/641) antibody, anti-
phospho-PKC-d (Thr 505) antibody, anti-C/EBP antibody, anti-RXR
antibody, anti-Sp1 antibody, anti-b-actin antibody from Cell Signal-
ing Technology (Beverly, MA), and anti-Mx antibody from Abcam
(Cambridge, UK). The signals of phosphorlylated proteins such as
phospho-PKC-a/b, -d and phospho-STAT1 were analyzed quantita-
tively using image analyzing software (ImageJ; version 1.45).
Small RNA interference
Stealth Select RNAi speciﬁc for STAT1 (HSS 10273) was
purchased from Invitrogen (Carlsbad, CA). Silencer Select siRNA
speciﬁc for C/EBP (ID: S2890), RXR (ID: S12386) and Sp1 (ID:
S13319) were purchased from Ambion (Austin, TX). Stealth RNAi
Negative Control Low GC Duplex (Invitrogen, Carlsbad, CA) was
used as a control for the off-target effect following Stealth Select
RNAi delivery. The transfections were carried out using Lipofec-
tamine RNAiMAX (Invitrogen, Carlsbad, CA) according to the
reverse transfection protocol.
Real-time reverse-transcription PCR
For cDNA synthesis, 1 mg of total RNA was reverse-transcribed
using High Capacity RNA-to-DNA Master Mix (Applied Biosystems,
Foster City, CA). cDNA, equivalent to 20 ng RNA, was used as a
template for real-time reverse-transcription PCR (RT-PCR) using
Applied Biosystems 7900HT Fast Real-Time PCR System (Applied
Biosystems, Foster City, CA). mRNA expressions of C/EBP, FTF, HNF1,
HNF3, and HNF4 were measured using TaqMan Gene Expression
Assays and were corrected with the quantiﬁed expressions level of
b-actin mRNA. Assay IDs for the genes were as follows: C/EBP
(Hs00269972_s1), FTF (Hs00187067_m1), HNF1 (Hs00167041_m1),
HNF3 (Hs00232754_m1), and HNF4 (Hs01023298_m1).For the detection of pgRNA and pre-C mRNA, the primers and
the probes were designed as follows according to a previous study
(Laras et al., 2002): the sense primer was 50-TCTTGTACATGTCC-
CACTGTTCAA-30 (nt 1843–1866); the anti-sense primer was
50-AATGCCATGCCCCAAAGC-30 (nt 1890–1909); the probe was
50-FAM-CTCCAAGCTGTGCCTT -30 (nt 1869–1884). Since they were
within precore/core coding sequence, only the total abundance of
pgRNA and pre-C RNA could be detected.
Statistical analysis
Data were presented as mean7SD. Differences between two
groups were determined using Student’s t-test for unpaired
observations. po0.05 was considered statistically signiﬁcant.Disclosures
All authors have nothing to disclose.
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